Skip to main content
SpringerLink
Log in

Antiinfektiva

  • Chapter
Pharmakotherapie in der Anästhesie und Intensivmedizin

  • 8459 Accesses

Zusammenfassung

Die Behandlung einer Infektion ist eine Hauptursache für die Aufnahme auf eine Intensivstation. Deren konsequente Behandlung hat eine erhebliche Bedeutung für das Überleben der Patienten und stellt, aufgrund der Verlängerung der Verweildauer, einen beachtlichen Kostenfaktor dar.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 99.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Literatur

  1. Agwuh KN, MacGowan A (2006) Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcydines. J Antimicrob Chemother 58:256–265

    Article  PubMed  CAS  Google Scholar 

  2. Aider J (2008) The use of daptomycin for Staphylococcus aureus infections in critical care medicine. Crit Care Clin 24:349–352

    Article  Google Scholar 

  3. Baldwin CM, Lyseng-Williamson KA, Keam SJ (2008) Meropenem: A Review of its Use in the Treatment of Serious Bacterial Infections. Drugs 68:

    Google Scholar 

  4. Baughman RP (2009) The Use of Carbapenems in the Treatment of Serious Infections. J Intensive Care Med 24:230–241

    Article  PubMed  Google Scholar 

  5. Boguniewicz M# Leung DY (1995) Hypersensitivity reactions to antibiotics commonly used in children. Pediatr Infect Dis J 14: 221–231

    Article  PubMed  CAS  Google Scholar 

  6. Bolon MK (2009) The newer fluoroquinolones. Infect Dis Clin North Am 23:1027–1051

    Article  PubMed  Google Scholar 

  7. Cha R, Sobel JD (2004) Fluconazole for the treatment of candidiasis: 15 years experience. Expert Rev Anti Infect Ther 2:357–366

    Article  PubMed  CAS  Google Scholar 

  8. Clark NM, Patterson J, Joseph P, III (2003) Antimicrobial resistance among gram-negative organisms in the intensive care unit. [Miscellaneous]. Current Opinion in Critical Care 9:413–423

    Article  PubMed  Google Scholar 

  9. Drawz SM, Bonomo RA (2010) Three Decades of {beta}-Lactama-se Inhibitors. Clin Microbiol Rev 23:160–201

    Article  PubMed  CAS  Google Scholar 

  10. Falagas ME, Kastoris AC, Kapaskelis AM, Karageorgopoulos DE (2010) Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum beta-lactamase producing, Enter-obacteriaceae infections: a systematic review. Lancet Infect Dis 10:43–50

    Article  PubMed  CAS  Google Scholar 

  11. Forrest GN, Tamura K (2010) Rifampin Combination Therapy for Nonmycobacterial Infections. Clin Microbiol Rev 23:14–34

    Article  PubMed  CAS  Google Scholar 

  12. Fromm LA, Graham DL (1999) Oxacillin-induced tissue necrosis. Ann Pharmacother 33:1060–1062

    Article  PubMed  CAS  Google Scholar 

  13. Garey KW, Salazar M, Shah D, Rodrigue R, DuPont HL (2008) Rifamycin Antibiotics for Treatment of Clostridium difficile-Associated Diarrhea. Ann Pharmacother 42:827–835

    Article  PubMed  CAS  Google Scholar 

  14. Guay D (2007) Update on clindamycin in the management of bacterial, fungal and protozoal infections. Expert Opin Pharmacother 8:2401–2444

    Article  PubMed  CAS  Google Scholar 

  15. Gums JG, Boatwright DW, Camblin M, Halstead DC, Jones ME, Sanderson R (2008) Differences Between Ceftriaxone and Cefotaxime: Microbiological Inconsistencies. Ann Pharmacother 42: 71–79

    Article  PubMed  CAS  Google Scholar 

  16. Howden B, Grayson M (2006) Antimicrobial Resistance: Dumb and Dumber. The Potential Waste of a Useful Antistaphylococcal Agent: Emerging Fusidic Acid Resistance in Staphylococcus aureus. Clinical Infectious Diseases 42:394–400

    Article  PubMed  CAS  Google Scholar 

  17. Jain R, Danziger LH (2004) The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr Pharm Des 10: 3045–3053

    Article  PubMed  CAS  Google Scholar 

  18. Johnson DM, Biedenbach DJ, Jones RN (2002) Potency and antimicrobial spectrum update for piperacillin/tazobactam (2000): emphasis on its activity against resistant organism populations and generally untested species causing community-acquired respiratory tract infections. Diagn Microbiol Infect Dis 43:49–60

    Article  PubMed  CAS  Google Scholar 

  19. Lichtenstern C, Nguyen TH, Schemmer P, Hoppe-Tichy T, Weigand MA (2008) Efficacy of caspofungin in invasive candidiasis and candidemia—de-escalation strategy. Mycoses 51: S35-S46

    Article  Google Scholar 

  20. Loo VG, Poirier L, Miller MA et al. (2005) A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N EngI J Med 353: 2442–2449

    Article  CAS  Google Scholar 

  21. MazzeiT, Novelli A (2009) Pharmacological properties of anti-fungal drugs with a focus on anidulafungin. Drugs 69: S79–S90

    Article  Google Scholar 

  22. Michalopoulos A, Falagas ME (2008) Colistin and polymyxin B in critical care. Crit Care Clin 24:377–391

    Article  PubMed  CAS  Google Scholar 

  23. Moise PA, North D, Steenbergen JN, Sakoulas G (2009) Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions. Lancet Infect Dis 9: 617–624

    Article  PubMed  CAS  Google Scholar 

  24. Musher D, Logan N, Bressler A, Johnson D, Rossignol J (2009) Nitazoxanide versus Vancomycin in Clostridium difficile Infection: A Randomized, Double Blind Study. Clinical Infectious Diseases 48: e41–e46

    Article  PubMed  CAS  Google Scholar 

  25. Nailor MD, Sobel JD (2009) Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am 23:965–982

    Article  PubMed  Google Scholar 

  26. Nicolau DP (2009) Management of complicated infections in the era of antimicrobial resistance: the role of tigecycline. Expert Opinion on Pharmacotherapy 10:1213–1222

    Article  PubMed  CAS  Google Scholar 

  27. Peterson LR (2005) Antimicrobial activity and pharmacokinetics/ pharmacodynamics of the novel glycylcycline, tigecycline. Diagn Microbiol Infect Dis 52:163–164

    Article  PubMed  CAS  Google Scholar 

  28. Rea RS, Capitano B (2007) Optimizing Use of Aminoglycosides in the Critically III. Semin Respir Crit Care Med 28:596–603

    Article  PubMed  Google Scholar 

  29. Roberts JABP, Lipman JF (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. [Article]. Critical Care Medicine 37: 840–851

    Article  PubMed  CAS  Google Scholar 

  30. Ruhe J+, Monson T, Bradsher R, Menon A (2005) Use of Long acting Tetracyclines for Methicillin Resistant Staphylococcus aureus Infections: Case Series and Review of the Literature. Clinical Infectious Diseases 40:1429–1434

    Article  PubMed  CAS  Google Scholar 

  31. Saner F, Gensicke J, Rath P et al. (2006) Safety profile of concomitant use of caspofungin and cyclosporine or tacrolimus in liver transplant patients. Infection 34:328–332

    Article  PubMed  CAS  Google Scholar 

  32. Schaad UB, Suter S, Gianella-Borradori A et al. (1990) A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N EngI J Med 322:141–147

    Article  CAS  Google Scholar 

  33. Sensakovic JW# Smith LG (1995) Beta-Iactamase inhibitor combinations. Med Clin North Am 79:695–704

    PubMed  CAS  Google Scholar 

  34. Stalker DJ, Jungbluth GL (2003) Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin Pharmacokinet 42:1129–1140

    Article  PubMed  CAS  Google Scholar 

  35. Svetitsky S, Leibovici L, Paul M (2009) Comparative Efficacy and Safety of Vancomycin versus Teicoplanin: Systematic Review and Meta-Analysis. Antimicrob Agents Chemother 53: 4069–4079

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universitätsklinikum Freiburg, Freiburg, Albertstrasse 23, 79104, Germany

    Prof. Dr. Jost Leemhuis

Authors
  1. Prof. Dr. Jost Leemhuis
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Klinik für Anästhesie, operative und allg. Intensivmedizin, Notfallmedizin, Klinikum Links der Weser gGmbH, Senator-Weßling-Str. 1, 28277, Bremen

    Peter H. Tonner

  2. Klinik für Anästhesie und Intensivmedizin, Klinikum Bremen Nord gGmbH, Hammersbecker Str. 228, 28755, Bremen

    Peter H. Tonner

  3. Institut für Exp. u. Klin. Pharmakologie u. Toxikologie - Abt. II, Universität Freiburg, Albertstraße 25, 79104, Freiburg

    Lutz Hein

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Leemhuis, J. (2011). Antiinfektiva. In: Tonner, P.H., Hein, L. (eds) Pharmakotherapie in der Anästhesie und Intensivmedizin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-79156-0_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-79156-0_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-79155-3

  • Online ISBN: 978-3-540-79156-0

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation